IMUX - NASDAQ

Immunic, Inc.

IMUX·NASDAQ

$14.64

+2.3%

HealthcareBiotechnology

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$144.48M

EPS-6.2400

P/E Ratio-0.86

Earnings Date08/06/2026

24.05M

Assets

-41%

3Y-81.0%

5Y-86.0%

10Y-62.0%

30.73M

Total Liabilities

37%

3Y+118.0%

5Y+239.0%

10Y+451.0%

-6.67M

Total Equity

-136%

3Y-106.0%

5Y-104.0%

10Y-111.0%

Immunic, Inc. Funding & Solvency Profile

IMUX · NASDAQ

Current Assets

Cash & Cash Equivalents15.48M

Net Receivables4.12M

Inventory0.00

Other Current Assets3.26M

Total Current Assets23 M

Non-Current Assets

Property, Plant & Equipment1.18M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets1 M

Total Assets

24.05M

Financial Health Analysis

Current Ratio

0.75x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Working Capital

-7749000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

95% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Immunic, Inc. Balance Sheet

IMUX • NASDAQ

Immunic, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	15.5M	35.7M	46.7M	106.7M	86.9M	127.5M	29.4M	13.3M	56.9M	60M	83.4M	102.2M	38.2M	4.5M	803K
Short-Term Investments	0.0	0.0	0.0	9.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14M	0.0
Cash & Short-Term Investments	15.5M	35.7M	46.7M	116.4M	86.9M	127.5M	29.4M	13.3M	56.9M	60M	83.4M	102.2M	38.2M	18.5M	803K
Net Receivables	4.1M	684K	703K	296K	2.2M	295K	408K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	684K	0.0	0.0	2.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	4.1M	0.0	703K	296K	0.0	295K	408K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	5.6M	0.0	0.0	-408K	-191K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	1.9M	2.3M	0.0	14.9M	4.7M	1.3M	908K	0.0	15.3K	1.1M	986K	1.2M	320K	86K
Other Current Assets	3.3M	1.1M	2.8M	3.6M	1.1M	1.3M	1.6M	0.0	1.2M	1.5M	533K	1.6M	3.5M	355K	0.0
Total Current Assets	22.9M	39.3M	52.5M	125.9M	105M	133.7M	32.2M	14.2M	58.1M	61.5M	85.1M	104.8M	43.9M	19.1M	889K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.2M	1.5M	1.8M	1.8M	1.1M	1.1M	713K	709K	2.2M	2.5M	3.8M	3.1M	2.5M	1.2M	1.1M
Goodwill	0.0	0.0	0.0	0.0	33M	33M	33M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	33M	33M	33M	0.0	0.0	3.1M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	0.0	0.0	43K	42K	42K	42K	37K	108K	-3M	184K	198K	263K	0.0	0.0
Total Non-Current Assets	1.2M	1.5M	1.8M	1.9M	34.1M	34.1M	33.7M	746K	2.3M	2.6M	4M	3.3M	2.7M	1.2M	1.1M
Total Assets	24.1M	40.9M	54.3M	127.8M	139.1M	167.9M	66M	15M	60.4M	64M	89.1M	108.1M	46.6M	20.3M	2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10.1M	7.8M	5.1M	4.3M	3.7M	3.7M	2.4M	268K	1M	780K	1.2M	1.2M	1.2M	1.1M	870K
Accounts Payable	10.1M	7.8M	5.1M	4.3M	3.5M	3.7M	2.4M	268K	1M	780K	1.2M	1.2M	1.2M	1.1M	870K
Other Payables	0.0	0.0	0.0	0.0	246K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	12.9M	1.5M	890K	6.4M	4.3M	3.3M	1.7M	3.6M	2.2M	2.2M	2.6M	512K	137K	11K
Short Term Debt	470K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	534K
Capital Lease Obligations (Current)	0.0	740K	695K	571K	408K	297K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	20M	676K	17.5M	7.3M	851K	82K	343K	564K	5.6M	2.5M	3.3M	6.6M	3M	464K	583K
Total Current Liabilities	30.6M	22.2M	24.7M	13.1M	11.4M	8.4M	7.1M	2.5M	10.3M	5.5M	6.7M	10.3M	4.8M	1.7M	2M
NON-CURRENT LIABILITIES
Long Term Debt	107K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-107K	0.0	0.0	0.0	0.0	0.0	0.0	41K	59K	100K	101K	241K	321K	26.2M	54.8M
Total Non-Current Liabilities	107K	264K	639K	992K	584K	679K	520K	41K	59K	100K	101K	241K	321K	26.2M	54.8M
Capital Lease Obligations	107K	1M	1.3M	1.6M	992K	976K	520K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	30.7M	22.4M	25.4M	14.1M	12M	9.1M	7.6M	2.6M	10.3M	5.6M	6.8M	10.5M	5.2M	28M	56.8M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	66M	37.2M	17.9M	0.0	0.0	108.1M	0.0	0.0	0.0
Common Stock	9K	8K	4K	4K	3K	2K	1K	4K	4K	3K	3K	2K	1K	0.0	0.0
Additional Paid-In Capital	599.2M	525.6M	436.1M	427.9M	324.2M	266.8M	119.6M	56K	345.9M	302.2M	285.1M	248.3M	144.5M	62.7M	8.8M
Retained Earnings	-608.6M	-511.4M	-410.9M	-317.3M	-196.9M	-103.9M	-59.9M	-337.4M	-296M	-243.8M	-202.9M	97.6M	-103.2M	-70.4M	-63.7M
Accumulated Other Comprehensive Income/Loss	2.6M	4.2M	3.8M	3M	-252K	-4.1M	-1.4M	80K	78K	83K	80K	89K	96K	88K	83K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	349.7M	0.0	0.0	0.0	-108.1M	0.0	128.3M	0.0
Total Stockholders' Equity	-6.7M	18.4M	28.9M	113.7M	127.1M	158.8M	58.4M	12.4M	50M	58.4M	82.3M	97.6M	41.4M	-7.6M	-54.9M
Total Equity	-6.7M	18.4M	28.9M	113.7M	127.1M	158.8M	58.4M	12.4M	50M	58.4M	82.3M	97.6M	41.4M	-7.6M	-54.9M
SUMMARY
Total Liabilities & Equity	24.1M	40.9M	54.3M	127.8M	139.1M	167.9M	66M	15M	60.4M	64M	89.1M	108.1M	46.6M	20.3M	2M
Total Investments	0.0	0.0	0.0	9.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14M	0.0
Total Debt	684K	1M	1.3M	1.6M	992K	976K	520K	37.2M	0.0	0.0	0.0	0.0	0.0	0.0	534K
Net Debt	-14.8M	-34.7M	-45.3M	-105.2M	-85.9M	-126.5M	-28.8M	23.9M	-56.9M	-60M	-83.4M	-102.2M	-38.2M	-4.5M	-269K
Shares Outstanding	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590	98,650,590

SEC Filings

IMUX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	May 29, 2026	June 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 28, 2026	May 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 27, 2026	May 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 19, 2026	May 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	April 30, 2026	April 30, 2026		View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 23, 2026	April 22, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 22, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 264 filings

Related Guides

Blog Categories

Continue your IMUX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.